132 related articles for article (PubMed ID: 8497920)
1. A phase II study of combination chemotherapy in advanced ovarian carcinoma with cisplatin and cyclophosphamide plus reduced glutathione as potential protective agent against cisplatin toxicity.
Locatelli MC; D'Antona A; Labianca R; Vinci M; Tedeschi M; Carcione R; Corbo A; Venturino P; Luporini G
Tumori; 1993 Feb; 79(1):37-9. PubMed ID: 8497920
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of high-dose cisplatin and cyclophosphamide with glutathione protection in the treatment of bulky advanced epithelial ovarian cancer.
Di Re F; Bohm S; Oriana S; Spatti GB; Zunino F
Cancer Chemother Pharmacol; 1990; 25(5):355-60. PubMed ID: 2306797
[TBL] [Abstract][Full Text] [Related]
3. High-dose cisplatin and cyclophosphamide with glutathione in the treatment of advanced ovarian cancer.
Di Re F; Bohm S; Oriana S; Spatti GB; Pirovano C; Tedeschi M; Zunino F
Ann Oncol; 1993 Jan; 4(1):55-61. PubMed ID: 8435364
[TBL] [Abstract][Full Text] [Related]
4. Dose intensification of platinum compounds with glutathione protection as induction chemotherapy for advanced ovarian carcinoma.
Böhm S; Oriana S; Spatti G; Di Re F; Breasciani G; Pirovano C; Grosso I; Martini C; Caraceni A; Pilotti S; Zunino F
Oncology; 1999; 57(2):115-20. PubMed ID: 10461057
[TBL] [Abstract][Full Text] [Related]
5. A cisplatinum-cyclophosphamide regimen in advanced ovarian cancer: reporting 5-year results.
Locatelli MC; D'Antona A; Carcione R; Cesana B; Dallavalle G; Vinci M; Clerici M; Labianca R; Pasquinucci C; Luporini G
Oncology; 1993; 50(2):92-9. PubMed ID: 8451042
[TBL] [Abstract][Full Text] [Related]
6. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest.
Gadducci A; Carnino F; Chiara S; Brunetti I; Tanganelli L; Romanini A; Bruzzone M; Conte PF
Gynecol Oncol; 2000 Feb; 76(2):157-62. PubMed ID: 10637064
[TBL] [Abstract][Full Text] [Related]
7. A preliminary clinical experience with reduced glutathione as protector against cisplatin-toxicity.
Oriana S; Böhm S; Spatti G; Zunino F; Di Re F
Tumori; 1987 Aug; 73(4):337-40. PubMed ID: 3660470
[TBL] [Abstract][Full Text] [Related]
8. A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies.
Hussein AM; Petros WP; Ross M; Vredenburgh JJ; Affrontil ML; Jones RB; Shpall EJ; Rubin P; Elkordy M; Gilbert C; Gupton C; Egorin MJ; Soper J; Berchuck A; Clarke-Person D; Berry DA; Peters WP
Cancer Chemother Pharmacol; 1996; 37(6):561-8. PubMed ID: 8612310
[TBL] [Abstract][Full Text] [Related]
9. Combined carboplatin plus ifosfamide and cisplatin in patients with advanced ovarian carcinoma. A phase I-II study. GOCS (Gynecological Oncology Cooperative Study).
Lorusso V; Leone B; Di Vagno G; Manzione L; Palmeri S; Vallejo C; Machiavelli M; Nacci G; Bilancia D; Leonardi V; Catino A; Gargano G; Loverro G; Selvaggi L; De Lena M
Gynecol Oncol; 1998 Feb; 68(2):172-7. PubMed ID: 9514802
[TBL] [Abstract][Full Text] [Related]
10. Cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin in stage III-IV ovarian carcinoma: a comparison of equally myelosuppressive regimens.
Edmonson JH; McCormack GM; Wieand HS; Kugler JW; Krook JE; Stanhope CR; Everson LK; Laurie JA; Ebbert LP; Malkasian GD
J Natl Cancer Inst; 1989 Oct; 81(19):1500-4. PubMed ID: 2674460
[TBL] [Abstract][Full Text] [Related]
11. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group).
McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
Semin Oncol; 1996 Oct; 23(5 Suppl 12):40-7. PubMed ID: 8941409
[TBL] [Abstract][Full Text] [Related]
12. Randomized study comparing carboplatin/cyclophosphamide and cisplatin/cyclophosphamide as first-line treatment in patients with stage III/IV epithelial ovarian cancer and small volume disease. German Ovarian Cancer Study Group (GOCA).
Meerpohl HG; Sauerbrei W; Kühnle H; Schumacher M; Pfleiderer A
Gynecol Oncol; 1997 Jul; 66(1):75-84. PubMed ID: 9234925
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin and cyclophosphamide in advanced ovarian carcinoma: activity and toxicity of an ambulatory regimen.
Zambetti M; Gianni L; Di Re F; Spatti G; Fontanelli R; Escobedo A; De Palo G; Bonadonna G
Am J Clin Oncol; 1990 Jun; 13(3):199-203. PubMed ID: 2161174
[TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer.
Soulié P; Bensmaïne A; Garrino C; Chollet P; Brain E; Fereres M; Jasmin C; Musset M; Misset JL; Cvitkovic E
Eur J Cancer; 1997 Aug; 33(9):1400-6. PubMed ID: 9337681
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group.
Swenerton K; Jeffrey J; Stuart G; Roy M; Krepart G; Carmichael J; Drouin P; Stanimir R; O'Connell G; MacLean G
J Clin Oncol; 1992 May; 10(5):718-26. PubMed ID: 1569444
[TBL] [Abstract][Full Text] [Related]
16. Mature results of a prospective randomized trial comparing a three-weekly with an accelerated weekly schedule of cisplatin in advanced ovarian carcinoma.
Cocconi G; Bella M; Lottici R; Leonardi F; Ceci G; Passalacqua R; Di Blasio B; Bordi C; Biscottini B; Melpignano M; De Biasi D; Finardi C; Bacchi M
Am J Clin Oncol; 1999 Dec; 22(6):559-67. PubMed ID: 10597739
[TBL] [Abstract][Full Text] [Related]
17. [Consensus and new development in epithelial ovarian cancer chemotherapy in 1995].
Hatae M; Onishi Y; Maeda Y; Nakamura T; Maeda T; Wada T
Gan To Kagaku Ryoho; 1995 Aug; 22(9):1182-9. PubMed ID: 7661570
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II study of paclitaxel, cisplatin, and cyclophosphamide in advanced ovarian carcinoma: preliminary results.
Coeffic D; Benhammouda A; Antoine EC; Rixe O; Paraiso D; Auclerc G; Nizri D; Renody N; Grapin JP; Mularoni E; Rattini E; Soubrane C; Weil M; Mortier N; Khayat D
Semin Oncol; 1996 Dec; 23(6 Suppl 15):5-8. PubMed ID: 8996589
[TBL] [Abstract][Full Text] [Related]
19. [Cyclic high dose CAP therapy by short-stay admission for ovarian malignancies--to increase total dose of CDDP and to improve quality of life of patients].
Ochiai K; Isonishi S; Kimura E; Yokoyama S; Sasaki H; Arihiro T; Terashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1991 Jan; 43(1):19-25. PubMed ID: 1997612
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
Thigpen T; Vance R; Puneky L; Khansur T
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
